Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is an experimental small molecule belonging to the class of methoxyphenols. It acts as an inhibitor of serine/threonine-protein kinase Chk1 (Checkpoint kinase 1), a key regulator in the DNA damage response pathway. By inhibiting Chk1, this molecule may interfere with cell cycle arrest and DNA repair mechanisms in cancer cells, potentially sensitizing them to DNA-damaging agents. The compound has not been approved for any indication and is primarily studied as a research tool or lead structure for anticancer drug development[1][4][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (3Z)-6-(4-hydroxy-3-methoxyphenyl)-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydro-2H-indol-2-one.